<DOC>
	<DOCNO>NCT01491672</DOCNO>
	<brief_summary>This study evaluate everolimus second-line therapy patient metastatic renal cell carcinoma . Each patient enrol stratify one three cohort base upon first-line therapy : 1 ) prior cytokine , 2 ) prior sunitinib , 3 ) prior anti-VEGF therapy sunitinib .</brief_summary>
	<brief_title>Everolimus Second-line Therapy Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Age ≥ 18 year old . 2 . Patients advance renal cell carcinoma histological cytological confirmation clear cell ( component clear cell ) renal carcinoma previously progress intolerant firstline therapy sunitinib , sorafenib , pazopanib , axitinib , bevacizumab , cytokine therapy . 3 . Patients must prior nephrectomy ( partial total ) . 4 . Patients least one measurable lesion baseline per RECIST 1.0 criterion . If skin lesion report target lesion , document ( baseline every physical exam ) use color photography measure device ( caliper ) clear focus allow size lesion ( ) determine photograph . 5 . Patients Karnofsky Performance Status ≥ 70 % . 6 . Adequate bone marrow function show : 1 . ANC ≥ 1.5 x 109/L , 2 . Platelets ≥ 100 x 109/L , 3 . Hemoglobin &gt; 9 g/dL 7 . Adequate liver function show : 1 . Serum bilirubin ≤ 1.5 x ULN , 2 . ALT AST ≤ 2.5 x ULN . Patients know liver metastasis may enroll AST ALT ≤ 5 x ULN , 3 . INR &lt; 1.3 ( INR &lt; 3 patient treated anticoagulant ) 8 . Adequate renal function : serum creatinine ≤ 2.0 x ULN . 9 . Fasting serum cholesterol ≤300 mg/dl OR ≤7.75 mmol/L AND fast triglyceride ≤2.5 x ULN . 10 . Written inform consent obtain trial related activity accord local guideline . 1 . Patients brain metastasis . 2 . Patients within 4 week postmajor surgery ( e.g. , intrathoracic , intraabdominal intrapelvic ) , open biopsy , significant traumatic injury avoid wound heal complication . Minor procedure percutaneous biopsy placement vascular access device require 7 day prior study entry . 3 . Patients anticipation need major surgical procedure course study . 4 . Patients radiation therapy within 4 week prior start study treatment ( palliative radiotherapy bone lesion allow 2 week prior study treatment start ) . 5 . Patients serious nonhealing wound , ulcer , bone fracture . 6 . Patients history seizure ( ) control standard medical therapy . 7 . Patients receive one prior treatment regimen metastatic renalcell carcinoma 8 . Patients receive adjuvant therapy RCC 9 . Patients previously receive systemic mTOR inhibitor ( eg , sirolimus , temsirolimus , everolimus ) 10 . Patients know hypersensitivity everolimus rapamycins ( eg , sirolimus , temsirolimus ) excipients . 11 . History clinical evidence central nervous system ( CNS ) metastases . 12 . Clinically significant gastrointestinal abnormality include , limited : 1 . Malabsorption syndrome : 2 . Major resection stomach small bowel could affect absorption study drug 3 . Active peptic ulcer disease 4 . Inflammatory bowel disease : i. Ulcerative colitis , gastrointestinal condition increase risk perforation ii . History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . 13 . Patients known history HIV seropositivity . Screening HIV infection baseline require . 14 . Active bleed diathesis 15 . Uncontrolled diabetes mellitus define fast serum glucose &gt; 2.0 x ULN . 16 . Patients severe and/or uncontrolled medical condition : 1. unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤ 6 month prior enrollment , serious uncontrolled cardiac arrhythmia , 2. active uncontrolled severe infection , 3. history invasive fungal infection , 4. severe hepatic impairment ( ChildPugh class C ) , 5. severely impaired lung function 17 . History cerebrovascular accident ( CVA ) include transient ischemic attack ( TIA ) ≤ 6 month start study treatment . 18 . History pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . 19 . Patients history another primary malignancy treatment ≤ 3 year , exception nonmelanoma skin cancer carcinoma situ uterine cervix breast , localized cancer bladder ( T1 ) prostate ( T1 T2 ) . 20 . Female patient pregnant nursing ( lactate ) . 21 . Adults reproductive potential use effective birth control method . Adequate contraceptive must use throughout trial 8 week last study drug administration female patient . Women childbearing potential must negative serum pregnancy test within 7 day prior first administration study drug . 22 . Patients use investigational agent receive investigational drug ≤ 2 week prior study treatment start . This include sunitinib , sorafenib , axitinib , pazopanib cytokine . 23 . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>Second Line</keyword>
	<keyword>Everolimus</keyword>
	<keyword>RAD001</keyword>
</DOC>